ANI Operating Income from 2010 to 2025

ANIP Stock

USD 66.33 0.35 0.53%

ANI Pharmaceuticals Operating Income yearly trend continues to be relatively stable with very little volatility. Operating Income is likely to grow to about 613.2 K this year. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit ANI Pharmaceuticals generates from its operations. View All Fundamentals

Operating Income

First Reported

1999-06-30

Previous Quarter

-20.5 M

Current Value

-4.4 M

Quarterly Volatility

7.8 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check ANI Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ANI Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 71.1 M, Interest Expense of 18.5 M or Selling General Administrative of 262.1 M, as well as many indicators such as Price To Sales Ratio of 1.65, Dividend Yield of 0.0012 or PTB Ratio of 2.37. ANI financial statements analysis is a perfect complement when working with ANI Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of ANI Pharmaceuticals Correlation against competitors.

To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.

Latest ANI Pharmaceuticals' Operating Income Growth Pattern

Below is the plot of the Operating Income of ANI Pharmaceuticals over the last few years. Operating Income is the amount of profit realized from ANI Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of ANI Pharmaceuticals is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. ANI Pharmaceuticals' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ANI Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Pretty Stable

Compare to Others All Fundamentals

Operating Income

Timeline

ANI Operating Income Regression Statistics

	Arithmetic Mean	3,218,273
	Geometric Mean	11,758,250
	Coefficient Of Variation	853.44
	Mean Deviation	22,158,386
	Median	898,000
	Standard Deviation	27,466,037
	Sample Variance	754.4T
	Range	97.9M
	R-Value	0.16
	Mean Square Error	786.7T
	R-Squared	0.03
	Significance	0.55
	Slope	942,706
	Total Sum of Squares	11315.7T

ANI Operating Income History

	2025	613.2 K
	2024	584 K
	2023	47 M
	2022	-25.1 M
	2021	-32.5 M
	2020	-16.1 M
	2019	16.4 M

Other Fundumenentals of ANI Pharmaceuticals

Non Operating Income Net Other

ANI Pharmaceuticals Operating Income component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Common Stock	Short Term Debt	Short Term Investments	Current Deferred Revenue	Net Receivables	Net Tangible Assets	Long Term Debt	Good Will	Long Term Debt Total	Long Term Investments	Treasury Stock	Intangible Assets	Property Plant Equipment	Capital Surpluse	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock	Accumulated Depreciation
Total Assets		0.96	0.7	0.0	0.97	0.99	0.96	-0.42	-0.22	0.17	0.69	0.98	0.18	0.97	0.94	0.62	0.75	-0.74	0.96	0.87	0.83	-0.74	0.85	0.75	0.82	-0.77
Total Stockholder Equity	0.96		0.69	0.07	0.93	0.91	0.97	-0.47	-0.17	0.17	0.68	0.95	0.21	0.89	0.86	0.69	0.57	-0.79	0.87	0.89	0.9	-0.76	0.81	0.8	0.85	-0.78
Net Debt	0.7	0.69		0.24	0.62	0.68	0.53	-0.47	-0.28	0.3	0.29	0.75	-0.38	0.62	0.55	0.59	0.34	-0.82	0.77	0.86	0.67	-0.78	0.47	0.37	0.55	-0.44
Retained Earnings	0.0	0.07	0.24		-0.15	-0.03	-0.05	-0.86	0.41	0.27	0.01	-0.04	-0.2	-0.05	-0.2	0.15	-0.18	-0.18	0.06	0.18	0.02	-0.06	-0.21	-0.24	-0.21	0.25
Accounts Payable	0.97	0.93	0.62	-0.15		0.96	0.96	-0.3	-0.36	0.25	0.64	0.98	0.27	0.94	0.96	0.57	0.74	-0.74	0.88	0.83	0.83	-0.73	0.88	0.83	0.87	-0.86
Total Liab	0.99	0.91	0.68	-0.03	0.96		0.93	-0.38	-0.24	0.17	0.68	0.97	0.17	0.99	0.96	0.56	0.83	-0.69	0.97	0.83	0.77	-0.71	0.84	0.7	0.77	-0.73
Total Current Assets	0.96	0.97	0.53	-0.05	0.96	0.93		-0.39	-0.19	0.14	0.74	0.94	0.37	0.92	0.91	0.61	0.67	-0.68	0.84	0.8	0.85	-0.7	0.85	0.83	0.85	-0.83
Common Stock	-0.42	-0.47	-0.47	-0.86	-0.3	-0.38	-0.39		-0.2	-0.32	-0.38	-0.4	-0.01	-0.37	-0.27	-0.43	-0.15	0.43	-0.42	-0.48	-0.42	0.36	-0.23	-0.21	-0.26	0.22
Short Term Debt	-0.22	-0.17	-0.28	0.41	-0.36	-0.24	-0.19	-0.2		-0.33	0.11	-0.33	0.1	-0.24	-0.33	-0.22	-0.18	0.33	-0.19	-0.28	-0.25	0.61	-0.34	-0.48	-0.4	0.34
Short Term Investments	0.17	0.17	0.3	0.27	0.25	0.17	0.14	-0.32	-0.33		-0.17	0.26	0.03	0.15	0.18	-0.02	0.06	-0.42	0.14	0.35	0.28	-0.27	0.24	0.23	0.28	-0.2
Current Deferred Revenue	0.69	0.68	0.29	0.01	0.64	0.68	0.74	-0.38	0.11	-0.17		0.65	0.31	0.7	0.66	0.39	0.56	-0.18	0.62	0.34	0.56	-0.37	0.59	0.6	0.55	-0.74
Net Receivables	0.98	0.95	0.75	-0.04	0.98	0.97	0.94	-0.4	-0.33	0.26	0.65		0.15	0.95	0.94	0.62	0.71	-0.79	0.93	0.89	0.85	-0.78	0.85	0.78	0.85	-0.82
Net Tangible Assets	0.18	0.21	-0.38	-0.2	0.27	0.17	0.37	-0.01	0.1	0.03	0.31	0.15		0.25	0.3	0.07	0.2	0.07	-0.02	-0.02	0.21	0.08	0.3	0.38	0.33	-0.35
Long Term Debt	0.97	0.89	0.62	-0.05	0.94	0.99	0.92	-0.37	-0.24	0.15	0.7	0.95	0.25		0.97	0.56	0.85	-0.62	0.95	0.78	0.75	-0.68	0.84	0.72	0.77	-0.72
Good Will	0.94	0.86	0.55	-0.2	0.96	0.96	0.91	-0.27	-0.33	0.18	0.66	0.94	0.3	0.97		0.47	0.85	-0.58	0.9	0.73	0.75	-0.62	0.89	0.77	0.84	-0.78
Long Term Debt Total	0.62	0.69	0.59	0.15	0.57	0.56	0.61	-0.43	-0.22	-0.02	0.39	0.62	0.07	0.56	0.47		0.3	-0.66	0.55	0.69	0.76	-0.74	0.58	0.63	0.6	-0.44
Long Term Investments	0.75	0.57	0.34	-0.18	0.74	0.83	0.67	-0.15	-0.18	0.06	0.56	0.71	0.2	0.85	0.85	0.3		-0.31	0.8	0.46	0.47	-0.35	0.78	0.51	0.53	-0.49
Treasury Stock	-0.74	-0.79	-0.82	-0.18	-0.74	-0.69	-0.68	0.43	0.33	-0.42	-0.18	-0.79	0.07	-0.62	-0.58	-0.66	-0.31		-0.69	-0.97	-0.76	0.81	-0.57	-0.53	-0.64	0.54
Intangible Assets	0.96	0.87	0.77	0.06	0.88	0.97	0.84	-0.42	-0.19	0.14	0.62	0.93	-0.02	0.95	0.9	0.55	0.8	-0.69		0.84	0.72	-0.69	0.76	0.59	0.69	-0.62
Property Plant Equipment	0.87	0.89	0.86	0.18	0.83	0.83	0.8	-0.48	-0.28	0.35	0.34	0.89	-0.02	0.78	0.73	0.69	0.46	-0.97	0.84		0.82	-0.83	0.67	0.6	0.72	-0.58
Capital Surpluse	0.83	0.9	0.67	0.02	0.83	0.77	0.85	-0.42	-0.25	0.28	0.56	0.85	0.21	0.75	0.75	0.76	0.47	-0.76	0.72	0.82		-0.75	0.87	0.86	0.93	-0.73
Short Long Term Debt	-0.74	-0.76	-0.78	-0.06	-0.73	-0.71	-0.7	0.36	0.61	-0.27	-0.37	-0.78	0.08	-0.68	-0.62	-0.74	-0.35	0.81	-0.69	-0.83	-0.75		-0.6	-0.69	-0.68	0.58
Net Invested Capital	0.85	0.81	0.47	-0.21	0.88	0.84	0.85	-0.23	-0.34	0.24	0.59	0.85	0.3	0.84	0.89	0.58	0.78	-0.57	0.76	0.67	0.87	-0.6		0.89	0.91	-0.74
Net Working Capital	0.75	0.8	0.37	-0.24	0.83	0.7	0.83	-0.21	-0.48	0.23	0.6	0.78	0.38	0.72	0.77	0.63	0.51	-0.53	0.59	0.6	0.86	-0.69	0.89		0.92	-0.81
Capital Stock	0.82	0.85	0.55	-0.21	0.87	0.77	0.85	-0.26	-0.4	0.28	0.55	0.85	0.33	0.77	0.84	0.6	0.53	-0.64	0.69	0.72	0.93	-0.68	0.91	0.92		-0.8
Accumulated Depreciation	-0.77	-0.78	-0.44	0.25	-0.86	-0.73	-0.83	0.22	0.34	-0.2	-0.74	-0.82	-0.35	-0.72	-0.78	-0.44	-0.49	0.54	-0.62	-0.58	-0.73	0.58	-0.74	-0.81	-0.8

Click cells to compare fundamentals

About ANI Pharmaceuticals Financial Statements

ANI Pharmaceuticals shareholders use historical fundamental indicators, such as Operating Income, to determine how well the company is positioned to perform in the future. Although ANI Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in ANI Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on ANI Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Operating Income	584 K	613.2 K
Non Operating Income Net Other	770.5 K	809 K

Additional Tools for ANI Stock Analysis

When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ANI Operating Income from 2010 to 2025

Latest ANI Pharmaceuticals' Operating Income Growth Pattern

ANI Operating Income Regression Statistics

ANI Operating Income History

Other Fundumenentals of ANI Pharmaceuticals

ANI Pharmaceuticals Operating Income component correlations

About ANI Pharmaceuticals Financial Statements

Additional Tools for ANI Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY